Literature DB >> 2606113

Hydroxyurea increases the phosphorylation of 3'-fluorothymidine and 3'-azidothymidine in CEM cells.

A Karlsson1, P Reichard, F Eckstein.   

Abstract

The triphosphates of the nucleoside analogues 3'-azidothymidine and 3'-fluorothymidine inhibit reverse transcriptase and are of therapeutic interest for the treatment of retrovirus infections. At equimolar concentrations 3'-fluorothymidine was more effectively transformed to the triphosphate by human CEM cells than azidothymidine which mainly accumulates as the monophosphate. Hydroxyurea, a drug that inhibits de novo synthesis of deoxyribonucleotides, considerably increased the ability of cells to phosphorylate both analogues. Addition of as little as 50 microM hydroxyurea decreased the amount of dideoxynucleoside required to attain a given intracellular concentration of its triphosphate by an order of magnitude. Hydroxyurea is known to shift the balance of substrate cycles between natural deoxynucleosides and their 5'-phosphates in the direction of synthesis and thereby to increase the import and intracellular phosphorylation of the nucleoside. The present results demonstrate a similar effect for the two analogues and raise the possibility of using this effect in therapy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2606113     DOI: 10.1111/j.1432-1033.1989.tb15261.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  8 in total

Review 1.  Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription.

Authors:  E J Arts; M A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

2.  Evaluation of reverse transcriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replication.

Authors:  C A Deminie; C M Bechtold; D Stock; M Alam; F Djang; A H Balch; T C Chou; M Prichard; R J Colonno; P F Lin
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

3.  In vitro combination of PNU-140690, a human immunodeficiency virus type 1 protease inhibitor, with ritonavir against ritonavir-sensitive and -resistant clinical isolates.

Authors:  K T Chong; P J Pagano
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

4.  Increased activation of the combination of 3'-azido-3'-deoxythymidine and 2'-deoxy-3'-thiacytidine in the presence of hydroxyurea.

Authors:  S Palmer; S Cox
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

5.  The anti-human immunodeficiency virus agent 3'-fluorothymidine induces DNA damage and apoptosis in human lymphoblastoid cells.

Authors:  R Sundseth; S S Joyner; J T Moore; R E Dornsife; I K Dev
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

6.  Disparate actions of hydroxyurea in potentiation of purine and pyrimidine 2',3'-dideoxynucleoside activities against replication of human immunodeficiency virus.

Authors:  W Y Gao; D G Johns; S Chokekuchai; H Mitsuya
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-29       Impact factor: 11.205

7.  Inhibition of ribonucleotide reductase by 2'-substituted deoxycytidine analogs: possible application in AIDS treatment.

Authors:  V Bianchi; S Borella; F Calderazzo; P Ferraro; L Chieco Bianchi; P Reichard
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-30       Impact factor: 11.205

8.  Surmounting Cytarabine-resistance in acute myeloblastic leukemia cells and specimens with a synergistic combination of hydroxyurea and azidothymidine.

Authors:  May Levin; Michal Stark; Bluma Berman; Yehuda G Assaraf
Journal:  Cell Death Dis       Date:  2019-05-17       Impact factor: 8.469

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.